fda glp-1 warning october 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA issues 30 warning letters

Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied

SA-SIBS Scholarship Program (L.H.Z

Having a sterile, sealed, empty vial on hand is good practice

Thus, researchers delved into the possible effects of Ipamorelin on gastric functions compared to placebo, with a spotlight on its purported ability to expedite gastric emptying

The experts at Joi advise a bare minimum of 100g of protein per day on GLP-1s , as a non-negotiable amount

As a 2026 review noted, the original composition-of-matter patents "have likely expired reducing the commercial exclusivity that typically incentivizes industry-sponsored Phase II and III development" [13]